Clinical TrialApr 21, 2026, 07:01 AM
Eupraxia's EP-104GI shows 66% remission at 36 weeks in EoE trial
AI Summary
Eupraxia Pharmaceuticals announced positive 36-week data from the highest dose cohort (Cohort 9) of its RESOLVE trial for EP-104GI in eosinophilic esophagitis (EoE). Patients demonstrated robust and sustained improvements in both tissue health and symptom response, with 66% maintaining clinical remission. The drug continues to be well-tolerated with no drug-related Serious Adverse Events reported, reinforcing its potential as a safe and effective treatment.
Key Highlights
- Cohort 9 showed 90% reduction in EoEHSS Stage and 88% reduction in Grade at 36 weeks.
- Peak Eosinophil Count (PEC) reduced by 72% from baseline in Cohort 9 at 36 weeks.
- 66% of Cohort 9 patients maintained clinical remission in symptoms from week 8 to 36.
- No drug-related Serious Adverse Events reported across 31 patients in the study.